Generic Ozempic Delayed: Health Canada Backlog Pushes Timeline to Q3 2026

Novo Nordisk’s eight-year data exclusivity period for semaglutide expired on January 4, 2026. This date marked the point at which Health Canada can legally approve generic versions of the drug. However, expiration of data exclusivity does not mean generics are immediately available — it simply means Health Canada can now process and approve the pending generic applications.

Nine generic manufacturers submitted applications to Health Canada in anticipation of this date. Each submission must go through Health Canada’s full review process for abbreviated new drug submissions (ANDS), which assesses bioequivalence, manufacturing quality, and labeling.

Health Canada targets a 180-day review period for generic drug submissions. However, the agency’s own performance data shows it is hitting this target only 84% of the time. For the remaining 16% of applications, reviews extend beyond the six-month window — sometimes significantly.

Several factors are contributing to the current backlog:

• Volume of semaglutide applications: Nine simultaneous submissions for the same reference product is unusually high and places additional demands on Health Canada’s review capacity.
• Peptide complexity: Semaglutide is a 31-amino-acid peptide with a fatty acid chain modification. This is not a simple small-molecule generic — the manufacturing process for injectable peptide drugs involves additional quality requirements that take longer to evaluate.
• Device review: Each generic submission includes a delivery device (injection pen) that must also meet Health Canada’s standards. Device variability between manufacturers adds review time.

Dr. Reddy’s Laboratories, the Indian pharmaceutical company, was among the first to file a generic semaglutide submission with Health Canada. On October 30, 2025, the company received a Notice of Non-Compliance (NON) — effectively a rejection of its initial application.

A Notice of Non-Compliance means Health Canada identified deficiencies in the submission that must be corrected before approval can be granted. Common reasons for NONs in generic drug reviews include:

• Bioequivalence data not meeting Health Canada’s requirements
• Manufacturing process or facility concerns
• Insufficient stability data for the proposed shelf life
• Device-related deficiencies

Dr. Reddy’s can resubmit its application after addressing the identified deficiencies. However, a resubmission restarts the review clock, effectively pushing Dr. Reddy’s estimated approval to 2027 at the earliest. The specific deficiencies cited in the NON have not been publicly disclosed.

The Dr. Reddy’s rejection highlights a broader challenge facing all generic semaglutide manufacturers. Semaglutide is not a typical small-molecule drug that can be reproduced using standard chemical synthesis.

Key manufacturing challenges include:

• Peptide synthesis: Semaglutide is a 31-amino-acid peptide, requiring either solid-phase peptide synthesis or recombinant DNA production. Both processes involve dozens of manufacturing steps with strict quality controls at each stage.
• Fatty acid modification: A C-18 fatty diacid chain is attached to the peptide backbone, which extends the drug’s half-life. The conjugation process must be precisely controlled to ensure the correct attachment site and purity.
• Formulation stability: Injectable peptide formulations require specific pH, buffer, and preservative conditions to maintain stability throughout the product’s shelf life.

These factors do not make generic semaglutide impossible — multiple manufacturers have clearly progressed through development — but they do make the regulatory review more rigorous than for simpler generics.

Two additional applicants have not been publicly identified. Review timelines are estimates based on publicly available information and may change.

While generic applicants navigate the review process, Novo Nordisk’s own lower-priced semaglutide brands may reach Canadian pharmacies first. Plosbrio (equivalent to Ozempic) and Poviztra (equivalent to Wegovy) were approved by Health Canada on December 22, 2025, and do not require additional regulatory review.

The remaining steps for Plosbrio and Poviztra are commercial: manufacturing scale-up, distribution agreements with pharmacy chains, and provincial formulary submissions. These are typically faster processes than regulatory approval, meaning Plosbrio and Poviztra could realistically reach pharmacy shelves before the first generic semaglutide product.

For details on Plosbrio and Poviztra, see our coverage: Plosbrio and Poviztra in Canada: Novo Nordisk’s Lower-Price Semaglutide, Explained.

While generic semaglutide timelines remain uncertain, there are factual steps consumers can take:

• Compare current prices. Prices for branded Ozempic vary significantly between pharmacies and provinces. Compare current prices on GLP1Prices.ca to find the lowest verified price in your area.
• Check insurance coverage. Some private insurance plans and provincial drug programs cover part or all of the cost of semaglutide. Coverage criteria vary by plan and province.
• Sign up for price alerts. Our generic price alert sends one email when verified generic or lower-cost semaglutide prices go live on the site.
• Monitor Health Canada decisions. Health Canada publishes drug approval decisions on its Drug Product Database.